Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Assets (2016 - 2025)

Historic Assets for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $21.2 million.

  • Abvc Biopharma's Assets rose 17226.92% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 17226.92%. This contributed to the annual value of $7.5 million for FY2024, which is 1240.0% up from last year.
  • As of Q3 2025, Abvc Biopharma's Assets stood at $21.2 million, which was up 17226.92% from $16.2 million recorded in Q2 2025.
  • Abvc Biopharma's Assets' 5-year high stood at $21.2 million during Q3 2025, with a 5-year trough of $6.7 million in Q4 2023.
  • For the 5-year period, Abvc Biopharma's Assets averaged around $11.5 million, with its median value being $10.5 million (2021).
  • As far as peak fluctuations go, Abvc Biopharma's Assets tumbled by 5312.24% in 2024, and later skyrocketed by 17226.92% in 2025.
  • Abvc Biopharma's Assets (Quarter) stood at $13.7 million in 2021, then tumbled by 30.07% to $9.6 million in 2022, then decreased by 29.97% to $6.7 million in 2023, then increased by 12.4% to $7.5 million in 2024, then soared by 180.86% to $21.2 million in 2025.
  • Its Assets stands at $21.2 million for Q3 2025, versus $16.2 million for Q2 2025 and $14.9 million for Q1 2025.